BRCANext®
Use
BRCANext is a 19-gene guideline-based panel intended to determine if a person has an inherited breast, ovarian, and/or endometrial cancer predisposition condition based on personal and/or family history. These genes have clinical management recommendations for detection, prevention, and risk reduction strategies. The test is particularly relevant for those with a family history of these cancers or other related risk factors, allowing for informed decision-making regarding surveillance, preventive measures, and treatment options.
Special Instructions
For patients with epithelial ovarian cancer only; non-epithelial ovarian cancers are not specifically targeted. Family variant testing is available at no additional cost for blood relatives of patients found to have a pathogenic or likely pathogenic variant, which must be completed within 90 days of the original report date.
Limitations
Variants in regions complicated by pseudogene interference, insufficient depth of coverage, and those below variant allele frequency quality thresholds might be undetectable. Intronic variants of uncertain significance beyond 5 base pairs from the splice junction are not reported. Gross deletion/duplication analysis is performed only for relevant genes, excluding ATRIP, POLD1, POLE, and RAD51B. Deletions in EPCAM are only reported if at the 3’ end. For PMS2, specific exons are reflexed for detailed analysis to confirm a result.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Phlebotomy draw recommended. Alternative specimens needed for patients with history of stem cell transplantation.
Causes for Rejection
Specimens from patients with a history of allogenic bone marrow or peripheral stem cell transplant are unacceptable.